Anayama T, Taguchi M, Tatenuma T, Okada H, Miyazaki R, Hirohashi K, Kume M, Matsusaki K, Orihashi K. In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report. World J Clin Cases 2019; 7(23): 4036-4043 [PMID: 31832406 DOI: 10.12998/wjcc.v7.i23.4036]
Corresponding Author of This Article
Takashi Anayama, MD, PhD, Associate Professor, Department of Surgery II, Kochi Medical School, Kochi University, 2-5-1akebono-cho, Kochi-shi, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Takashi Anayama, Mai Taguchi, Takehiro Tatenuma, Hironobu Okada, Ryohei Miyazaki, Kentaro Hirohashi, Motohiko Kume, Kazumasa Orihashi, Department of Surgery II, Kochi Medical School, Kochi University, Kochi 783-8505, Japan
Keisuke Matsusaki, Japanese CART Study Group, Kaname Second Clinic, Kanamecho Hospital, Tokyo 171-0043, Japan
Author contributions: Anayama T organized the entire study protocol and mainly wrote the manuscript; Taguchi M and Tatenuma T performed the CD-DST; Okada H and Kume M performed the KM-CART; Miyazaki R, Hirohashi K, and Kume M were responsible for the clinical treatment of the patient; Orihashi K was responsible for the entire study.
Informed consent statement: The patient agreed to all treatments. Every treatment was performed after obtaining written informed consent from the patient.
Conflict-of-interest statement: The authors have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Takashi Anayama, MD, PhD, Associate Professor, Department of Surgery II, Kochi Medical School, Kochi University, 2-5-1akebono-cho, Kochi-shi, Kochi 783-8505, Japan. anayamat@kochi-u.ac.jp
Telephone: +81-88-8802375 Fax: +81-88-8802376
Received: August 13, 2019 Peer-review started: August 13, 2019 First decision: September 23, 2019 Revised: November 8, 2019 Accepted: November 14, 2019 Article in press: November 14, 2019 Published online: December 6, 2019
Abstract
BACKGROUND
We report the first case, to the best of our knowledge, of massive ascites due to recurrent malignant pleural mesothelioma that was controlled using KM-cell-free and concentrated ascites reinfusion therapy (KM-CART). The tumor cells derived via KM-CART were utilized secondarily in an in vitro cell growth assay using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to investigate anticancer drug susceptibility.
CASE SUMMARY
A 56-year-old man presented with recurrent malignant mesothelioma with massive ascites; more than 4000 mL of ascitic fluid was removed, filtered, and concentrated using KM-CART, and the cell-free ascitic fluid was reinfused into the patient to improve quality of life. Cancer cells isolated secondarily in an in vitro proliferation assay using CD-DST exhibited low sensitivity to pemetrexed and high sensitivity to gemcitabine. Treatment with gemcitabine maintained stable disease for 4 mo.
CONCLUSION
The combination of KM-CART and CD-DST may be a promising treatment option for malignant ascites associated with malignant mesothelioma.
Core tip: Massive ascites due to recurrent malignant mesothelioma was controlled with innovative cell-free and concentrated ascites reinfusion therapy, and the derived tumor cells were utilized secondarily in an in vitro cell growth assay that contributed to the personalized chemotherapy for the patient.
